Merus Past Earnings Performance

Past criteria checks 0/6

Merus's earnings have been declining at an average annual rate of -28.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 5.8% per year.

Key information

-28.2%

Earnings growth rate

-9.4%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate5.8%
Return on equity-34.8%
Net Margin-680.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Merus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2GH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2436-2457546
30 Jun 2435-168670
31 Mar 2438-150610
31 Dec 2344-155600
30 Sep 2346-1775991
30 Jun 2341-178590
31 Mar 2343-152560
31 Dec 2242-131520
30 Sep 2246-64480
30 Jun 2253-54450
31 Mar 2252-76430
31 Dec 2149-67410
30 Sep 2143-80400
30 Jun 2138-89390
31 Mar 2132-79360
31 Dec 2030-86360
30 Sep 2029-83350
30 Jun 2028-69340
31 Mar 2029-65340
31 Dec 1931-55320
30 Sep 1937-32430
30 Jun 1935-34380
31 Mar 1936-26330
31 Dec 1838-28290
30 Sep 1834-41130
30 Jun 1833-45140
31 Mar 1834-66160
31 Dec 1726-78170
30 Sep 1718-100180
30 Jun 1712-87130
31 Mar 176-6690
31 Dec 163-5050
30 Sep 164-2520
30 Jun 163-2620
31 Mar 163-2710
31 Dec 152-2510
30 Sep 152-2510
30 Jun 152-23-10
31 Mar 151-2000
31 Dec 142-2110
31 Dec 131-1440

Quality Earnings: 2GH is currently unprofitable.

Growing Profit Margin: 2GH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2GH is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.

Accelerating Growth: Unable to compare 2GH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2GH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 2GH has a negative Return on Equity (-34.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 05:03
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Merus N.V. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research